Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Entrada Therapeutics (Nasdaq: TRDA) will present at the 44th Annual J.P.

Rhea-AI Summary

Entrada Therapeutics (Nasdaq: TRDA) will present at the 44th Annual J.P. Morgan Healthcare Conference. Dipal Doshi, CEO, will deliver the company presentation on Wednesday, January 14, 2026 at 3:45 PM PT (6:45 PM ET). A live webcast will be available on Entrada’s Investor Relations site and will be archived for 30 days after the event.

Argus Dec 17 session

-1.32% close to close Open Argus

Details

News Market Reaction – TRDA

On Dec 17, the day this news came out, TRDA closed 1.32% below the previous close.

Data tracked by StockTitan Argus for the Dec 17 session.

Market Context

This announcement details Entrada’s upcoming presentation at the 44th Annual J.P. Morgan Healthcare ...

Analysis

This announcement details Entrada’s upcoming presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, with a webcast and 30-day replay. It continues a series of investor-relations and conference updates following Q3 2025 results and prior event appearances. Investors tracking the story may focus on any new strategic, pipeline, or financial commentary delivered at the conference relative to previously disclosed cash of $326.8M and runway into Q3 2027.

Key Figures

Conference date: January 14, 2026 Presentation time PT: 3:45 PM PT Presentation time ET: 6:45 PM ET +1 more

Conference date

January 14, 2026

J.P. Morgan Healthcare Conference presentation date

Presentation time PT

3:45 PM PT

Scheduled start time of company presentation

Presentation time ET

6:45 PM ET

Eastern Time for the presentation

Webcast replay period

30 days

Archive availability on Investor Relations website

Historical Context

5 past events · Latest: Dec 04

5 events

1. Dec 04

   Inducement grants

   24h Move

   +1.6%

   Equity awards to new hires under 2025 Inducement Equity Plan.

2. Nov 06

   Earnings update

   24h Move

   +0.1%

   Q3 2025 financial results and DMD pipeline timing updates.

3. Oct 28

   Investor conferences

   24h Move

   +0.6%

   Participation in Jefferies and Evercore healthcare investor events.

4. Sep 05

   Community grants

   24h Move

   +1.3%

   DREAMS grants of $50,000 each to two nonprofits.

5. Sep 02

   Inducement grants

   24h Move

   -1.1%

   RSU and option grants to seven new non-executive employees.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that Dipal Doshi, Chief Executive Officer, will deliver a company presentation at the 44^th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 3:45 PM PT (6:45 PM ET).

A live webcast will be available on the Presentations portion of Entrada’s Investor Relations website at https://ir.entradatx.com. The webcast will be archived and available for replay for 30 days after the event.

About Entrada Therapeutics
Entrada Therapeutics is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company’s Endosomal Escape Vehicle (EEV™)-therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through this proprietary, versatile and modular approach, Entrada is advancing a robust development portfolio of RNA- and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. The Company’s lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne who are exon 44, 45, 50 and 51 skipping amenable. Entrada has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

For more information about Entrada, please visit our website, www.entradatx.com, and follow us on LinkedIn.

Investor Contact
Karla MacDonald
Chief Corporate Affairs Officer
kmacdonald@entradatx.com

Media Contact
Megan Prock McGrath
CTD Comms, LLC
megan@ctdcomms.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Entrada Therapeutics (TRDA) present at the J.P. Morgan Healthcare Conference?

Entrada will present on January 14, 2026 at 3:45 PM PT (6:45 PM ET).

Who is presenting for Entrada Therapeutics (TRDA) at the January 2026 J.P. Morgan conference?

Dipal Doshi, chief executive officer, will deliver the company presentation.

How can investors watch Entrada Therapeutics (TRDA) presentation on January 14, 2026?

A live webcast will be available on Entrada’s Investor Relations website's Presentations section.

Will the Entrada Therapeutics (TRDA) webcast be available after the J.P. Morgan presentation?

Yes. The webcast will be archived and available for replay for 30 days after the event.

Where on Entrada’s site can I find the January 14, 2026 presentation webcast?

The webcast will be posted on the Presentations portion of Entrada’s Investor Relations website.